Get started
Author

Yuqiang Mi

Observed names: Mi Yuqiang, Y Q Mi, Y.-Q. Mi, Y.‐Q. Mi, Yu-Qiang Mi, Yu-qiang Mi, YuQiang Mi, Yu‐Qiang Mi
Observed institutions: Nankai University, First Affiliated Hospital of Wenzhou Medical University, Sir Run Run Shaw Hospital, Tianjin Infectious Diseases Hospital, Tianjin Fourth Central Hospital, Tianjin Fourth Hospital, Tianjin Medical University, Marmara University, Zhejiang University
ORCID: 0000-0001-7809-2679
Observed ORCIDs: 0000-0001-7809-2679, 0000-0001-9930-6429
OpenAlex ID: A5036647827
Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis
2016 · Thomas Karlas, David Petroff, et al. · Journal of Hepatology · 1,337
Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder
2020 · Junjian Hu, Hongwu Wang, et al. · Theranostics · 111
Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
2015 · Feng Shen, Rui‐Dan Zheng, et al. · Liver International · 96
PDF
Clinical and histological features under different nomenclatures of fatty liver disease: NAFLD, MAFLD, MASLD and MetALD
2023 · Lin Chen, Xuemei Tao, et al. · Journal of Hepatology · 94
A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B
2017 · Liang Xu, Wei Lu, et al. · Digestive and Liver Disease · 77
Moderate to severe hepatic steatosis leads to overestimation of liver stiffness measurement in chronic hepatitis B patients without significant fibrosis
2019 · Feng Shen, Yu‐Qiang Mi, et al. · Alimentary Pharmacology & Therapeutics · 61
Impact of controlled attenuation parameter on detecting fibrosis using liver stiffness measurement
2018 · T. Karlas, D. Petroff, et al. · Alimentary Pharmacology & Therapeutics · 54
PDF
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD
2025 · Xiao-Dong Zhou, Yu-Ting Li, et al. · Clinical Gastroenterology and Hepatology · 47
PDF
Controlled Attenuation Parameter for Noninvasive Assessment of Hepatic Steatosis Using Fibroscan®: Validation in Chronic Hepatitis B
2014 · Yu-Qiang Mi, Qi-Yu Shi, et al. · Digestive Diseases and Sciences · 42
Vitamin E (300 mg) in the treatment of MASH: A multi-center, randomized, double-blind, placebo-controlled study
2025 · Yu Song, Wenjing Ni, et al. · Cell Reports Medicine · 36
APOC3 rs2070666 Is Associated with the Hepatic Steatosis Independently of PNPLA3 rs738409 in Chinese Han Patients with Nonalcoholic Fatty Liver Diseases
2016 · Rui-Nan Zhang, Rui-Dan Zheng, et al. · Digestive Diseases and Sciences · 29
Hepatocyte apoptosis fragment product cytokeratin-18 M30 level and non-alcoholic steatohepatitis risk diagnosis: an international registry study
2023 · Huai Zhang, Rafael S. Rios, et al. · Chinese Medical Journal · 28
An-Luo-Hua-Xian Pill Improves the Regression of Liver Fibrosis in Chronic Hepatitis B Patients Treated with Entecavir
2022 · Yi-Qi Liu, Chi Zhang, et al. · Journal of Clinical and Translational Hepatology · 27
PDF
HIV-1 Genetic Diversity and High Prevalence of Pretreatment Drug Resistance in Tianjin, China
2020 · Rui Zeng, Doudou Ren, et al. · AIDS Research and Human Retroviruses · 27
Epidemiological and clinical characteristics of bacteremic brucellosis
2020 · Chunhua Qie, Junwen Cui, et al. · Journal of International Medical Research · 25
PDF
Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease
2018 · Rui-Nan Zhang, Qin Pan, et al. · International Journal of Molecular Medicine · 24
PDF
The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China
2021 · Rui-Xu Yang, Zheng-Sheng Zou, et al. · Hepatobiliary & pancreatic diseases international · 23
Diagnostic value of alcoholic liver disease (ALD)/nonalcoholic fatty liver disease (NAFLD) index combined with γ-glutamyl transferase in differentiating ALD and NAFLD
2016 · Junling Wang, Ping Li, et al. · The Korean Journal of Internal Medicine · 21
PDF
ACT001 Alleviates chronic kidney injury induced by a high-fat diet in mice through the GPR43/AMPK pathway
2023 · Yibing Zhou, Ze Chen, et al. · Lipids in Health and Disease · 18
PDF
Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma
2024 · Jiaxin Han, Wentao Kuai, et al. · Cancer Biology and Medicine · 16
Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease
2024 · Ming-Hui Zeng, Qi-Yu Shi, et al. · World Journal of Gastroenterology · 16
Thyroid-stimulating hormone is associated with nonalcoholic steatohepatitis in patients with chronic hepatitis B
2019 · Liang Liu, Ping Li, et al. · Medicine · 14
Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease
2021 · Yi-Wen Shi, Fang-Ping He, et al. · Journal of Clinical and Translational Hepatology · 11
Efficacy of a Chinese herbal formula on hepatitis B e antigen-positive chronic hepatitis B patients
2020 · Yu-Feng Xing, Chun-Shan Wei, et al. · World Journal of Gastroenterology · 10
Hollow multishelled heterostructures with enhanced performance for laser desorption/ionization mass spectrometry based metabolic diagnosis
2023 · Congcong Pei, Rui Su, et al. · Journal of Materials Chemistry B · 9
PDF
Works count: 94
Citation count: 2,446
H-index: 19
I10-index: 25
Year
Topic
Type